Morphic believes oral drugs targeting the integrin protein family can transform the treatment paradigm for patients suffering from serious chronic diseases across the areas of autoimmunity, fibrosis and cancer.
Morphic’s initial portfolio is based on both novel and highly validated targets. Our development activity prioritizes diseases with validated clinical endpoints and biomarkers designed to support rapid proof-of-concept.
Morphic is developing highly differentiated molecules for the treatment of autoimmune diseases, fibrotic diseases, and cancer. We have created a balanced portfolio of novel and highly validated targets.